logo

For the Inventor, By the Inventor

Nagano, Japan

Kissei Pharmaceutical Co., Ltd.


USPTO Granted Patents = 176



Trademarks = 5

Forward Citations = 786

Loading Chart...
Loading Chart...

198 inventors (with patents filed for the assignee):

goldMedal Masayuki Isaji (38 out of 38 patents)

silverMedal Hideki Fujikura (32 out of 32 patents)

bronzeMedal Nobuhiko Fushimi (31 out of 31 patents)

4.  Kazuo Shimizu (21 out of 21 patents)

5.  Toshihiro Nishimura (21 out of 21 patents)

6.  Norihiko Kikuchi (17 out of 17 patents)

7.  Tetsuro Tamai (16 out of 16 patents)

8.  Nobuyuki Tanaka (16 out of 16 patents)

9.  Kinji Iizuka (16 out of 19 patents)

10.  Harunobu Mukaiyama (13 out of 13 patents)

11.  Tetsuhide Kamijo (13 out of 16 patents)

12.  Hideki Takeuchi (12 out of 12 patents)

13.  Masahiro Hiratochi (12 out of 12 patents)

14.  Kenji Katsuno (12 out of 12 patents)

15.  Kazuya Tatani (12 out of 12 patents)


Core Competencies:
Adenomyosis Treatment
Endometriosis Therapy
Gonadotropin-Releasing Hormone Antagonists
Hypoxanthine Compounds
Fused Heterocyclic Derivatives
Pyrazole Derivatives
Indole Derivatives
Genetically-Modified Cells
Pharmaceutical Compositions
Nitrogen Containing Heterocycles
Therapeutic Agents
Medical Applications

176 patents:

1. 12280052 - Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis (2025-04-21),
2. 12171878 - Sucroferric oxyhydroxide-containing granules and pharmaceutical composition (2024-12-24),
3. 12157739 - Hypoxanthine compounds (2024-12-03),
4. 12077531 - Imidazopyridinone compound (2024-09-03),
5. 11980621 - Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis (2024-05-14),
6. 11759464 - Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss (2023-09-19),
7. 11596644 - Method for treating post-prandial hypoglycemia (2023-03-07),
8. 11382914 - Usage and dosage of therapeutic agents for endometriosis (2022-07-12),
9. 10995084 - Pyrrolidine derivative (2021-05-04),
10. 10683355 - Genetically-modified cells and method for producing same (2020-06-16),
11. 10646491 - Usage and dosage of therapeutic agents for endometriosis (2020-05-12),
12. 10576084 - Salt of fused heterocyclic derivative and crystal thereof (2020-03-03),
13. 10399949 - NK1 receptor antagonist (2019-09-03),
14. 10287251 - Pyrazole derivative or pharmaceutically acceptable salt thereof (2019-05-14),
15. 10100030 - Carboxymethyl piperidine derivative (2018-10-16),
KISSEI PHARMACEUTICAL CO., LTD. is a leading pharmaceutical company based in Japan. With a focus on research, development, and production of innovative medical products, KISSEI PHARMACEUTICAL aims to contribute to the well-being of people worldwide. For over 70 years, the company has been providing high-quality medicines and healthcare solutions, addressing various therapeutic areas such as urology, dermatology, and more. KISSEI PHARMACEUTICAL is committed to delivering advanced pharmaceuticals that meet the evolving needs of patients and healthcare professionals.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

176 Patents

#9 in Nagano

#749 in Japan

#4,604 in the World

...
Nagano, Japan

Kissei Pharmaceutical Co., Ltd.

Forward Citations = 786

198 inventors:

goldMedal Masayuki Isaji (38 out of 38 patents)

silverMedal Hideki Fujikura (32 out of 32 patents)

bronzeMedal Nobuhiko Fushimi (31 out of 31 patents)

4.  Kazuo Shimizu (21 out of 21 patents)

5.  Toshihiro Nishimura (21 out of 21 patents)

Please report any incorrect information to support@idiyas.com
Loading…